MRK logo
MRK@NYSE
Merck & Co., Inc.
$ 145.60+3.22 (+2.26%)
Buy MRK
OpenPrice at market open
—
LowLowest price today
—
52-Week HighHighest past 52 weeks
—
HighHighest price today
—
52-Week LowLowest past 52 weeks
—
Market Cap.Total company value
351.69B
Today’s VolumeShares traded today
7.97M
Avg. VolumeAverage shares traded
10.42M
P/E RatioPrice to earnings ratio
113.01

Company Profile

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

IPO Date
1978-01-13
Headquarters
Rahway, US
CEO
Robert Davis
Sector
Healthcare
Industry
Drug Manufacturers - General

Financial Statements

Earnings

Related Companies

ABBV logo
ABBVAbbVie Inc.
276.47
AMGN logo
AMGNAmgen Inc.
414.87
AZN logo
AZNAstraZeneca PLC
159.20
GILD logo
GILDGilead Sciences, Inc.
151.17

Unlok the Future of Trading

Seamless access to global markets with AI-powered insights for smarter, more confident trading.

Device mockup